Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $229.50 | Total: $1,147.50 |
| 1 | 10 | $194.40 | Total: $1,944.00 |
| 1 | 25 | $164.70 | Total: $4,117.50 |
| 1 | 50 | $140.40 | Total: $7,020.00 |
| 1 | 100 | $121.50 | Total: $12,150.01 |
Overview
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.
Chemical Properties
| Molecular Formula | C33H42F3N9O2S2 |
| Molecular Weight | 717.871 |
| CAS Numbers | 2134675-36-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CNc1nc(NC2CCN(Cc3ccc4n(C[C@H](C)N5CCN(CC5)S(C)(=O)=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Rausch J, et al. Menin inhibitor ziftomenib [KO-539] synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023 Oct 1;108[10] 2837-2843.